Elevation Wealth Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Elevation Wealth Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.69K	Sell	47 -353	-88%	-$19.3K	﹤0.01%	1150
2026 Q1	$22.6K	Hold	400	–	–	0.01%	353
2025 Q4	$23.8K	Buy	400 +397	+13,233%	+$21.6K	0.01%	334
2025 Q3	$163	Hold	3	–	–	﹤0.01%	854
2025 Q2	$165	Hold	3	–	–	﹤0.01%	460
2025 Q1	$213	Hold	3	–	–	﹤0.01%	462
2024 Q4	$198	Hold	3	–	–	﹤0.01%	467
2024 Q3	$211	Hold	3	–	–	﹤0.01%	450
2024 Q2	$247	Hold	3	–	–	﹤0.01%	477
2024 Q1	$263	Hold	3	–	–	﹤0.01%	444
2023 Q4	$266	Hold	3	–	–	﹤0.01%	416
2023 Q3	$266	Hold	3	–	–	﹤0.01%	315
2023 Q2	$261	Hold	3	–	–	﹤0.01%	327
2023 Q1	$292	Buy	+3	New	+$311	﹤0.01%	327

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Elevation Wealth Partners's BMRN Position: Q2 2026 in Review

Elevation Wealth Partners reduced its BioMarin Pharmaceuticals (BMRN) stake by 88% in Q2 2026, selling an estimated $19.3K and leaving 47 shares worth $2.69K. The position accounts for ﹤0.01% of the portfolio, ranked #1150.

Elevation Wealth Partners first reported a position in BMRN in Q1 2023 and has held it in 14 quarters since. The position peaked at $23.8K in Q4 2025. 154 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Elevation Wealth Partners held 47 shares of BioMarin Pharmaceuticals worth $2.69K as of Q2 2026.
Elevation Wealth Partners sold 353 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $19.3K.
BioMarin Pharmaceuticals made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #1150 holding.
Elevation Wealth Partners first reported a position in BioMarin Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Elevation Wealth Partners's BioMarin Pharmaceuticals position peaked at $23.8K in Q4 2025.
154 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.